Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) Director Douglas Clark Wurth bought 12,500 shares of the stock in a transaction on Saturday, March 14th. The shares were bought at an average price of $2.00 per share, for a total transaction of $25,000.00. Following the purchase, the director directly owned 12,608 shares in the company, valued at approximately $25,216. This trade represents a 11,574.07% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Bluejay Diagnostics Trading Up 3.0%
BJDX stock traded up $0.05 during trading on Monday, reaching $1.72. The stock had a trading volume of 34,940 shares, compared to its average volume of 155,600. The stock’s 50 day moving average is $1.90 and its two-hundred day moving average is $3.24. Bluejay Diagnostics, Inc. has a 52 week low of $1.63 and a 52 week high of $16.68. The firm has a market cap of $1.77 million, a PE ratio of -0.15 and a beta of 0.72.
Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.
Institutional Trading of Bluejay Diagnostics
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Bluejay Diagnostics presently has an average rating of “Sell”.
Read Our Latest Research Report on Bluejay Diagnostics
Bluejay Diagnostics Company Profile
Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.
Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.
Featured Articles
- Five stocks we like better than Bluejay Diagnostics
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
